These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23314196)

  • 21. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH; Yang W; Qi JS
    Sheng Li Xue Bao; 2010 Oct; 62(5):398-406. PubMed ID: 20945041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
    Yang Y; Zhang J; Ma D; Zhang M; Hu S; Shao S; Gong CX
    J Alzheimers Dis; 2013; 37(3):637-48. PubMed ID: 23948890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.
    Li L
    CNS Drugs; 2017 Jul; 31(7):535-549. PubMed ID: 28540646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.
    Ma DL; Chen FQ; Xu WJ; Yue WZ; Yuan G; Yang Y
    J Neurochem; 2015 Oct; 135(2):301-8. PubMed ID: 26183127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
    CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
    Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.
    Farr S; Baker C; Naples M; Taher J; Iqbal J; Hussain M; Adeli K
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1092-100. PubMed ID: 25675997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
    Tramutola A; Arena A; Cini C; Butterfield DA; Barone E
    Expert Rev Neurother; 2017 Jan; 17(1):59-75. PubMed ID: 27715341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.